Summary The cure rates of two treatment regimens in PB leprosy were compared in a prospective randomized trial: treatment U consisting of a single dose of rifampicin 40 mg/K bodyweight, and treatment A of rifampicin 1500 mg in a single dose, fo llowed by one year of daily dapsone 100 mg. In patients with a Bl = 0, the cure rates evaluated on the basis of histopathology of skin biopsies, were identical for the two regimens but in patients with a BI = I, cure and relapse rates were unacceptable. For this reason and particularly the need to separate patients on the basis of the BI in skin biopsies, the single dose regimen does not appear to be suited for wide-scale application.
In previous studies several rifampicin (RMP) containing regimens have been shown to cure paucibacillary (PB) leprosy. ! ,2 The shortest regimen consisted of 6 daily doses of 600 mg RMP together with 100 mg dapsone (DDS),2 while the regimen containing the smallest amount ofRMP consisted of RMP 1500 mg as a single dose fo llowed by one year of DDS 100 mg daily.! Since in the latter regimen it may be expected that not all DDS tablets delivered to the patients were actually taken,3 the role of the associated DDS may be questioned.
In the mouse fo otpad model for experimental chemotherapy a single dose of 40 mg/K body weight of RMP prevents the multiplication of inocula of 5·1 03 to 104 My cobacterium
0305-751 8/9 1 /062 179+07 SO I .OO © Lepra leprae.4,5 Since PB patients harbour not more than 107 M. leprae6 a study on the activity of a single dose of RMP in PB leprosy may be justified.
A prospective controlled trial was therefore undertaken to compare the efficacy of a single dose of RMP, 40 mg/K body weight, with the previously evaluated regimen consisting of RMP 1500 mg, single dose, fo llowed by one year of daily 100 mg DDS.
Patients and methods
Leprosy patients were diagnosed after self-reporting or through referral. They were examined clinically and neurologically by experienced doctors or paramedical workers. Skin smears were taken from an earlobe and two skin lesions or two earlobes and the skin lesion when it was solitary. All patients were biopsied at the most active site and the biopsy, fixed in 10% fo rmalin or Lowy's fixative, was sent to Antwerp, where sections were stained by the Trichrome-Fite-Farracco technique.7 Copies of all clinical files at the start and at fo llow-up examinations were also sent to Antwerp.
PB patients were defined as having clinical TT or BT leprosy with a bacteriological index (BI) of not more than I (Ridley scale),? at any site examined and confirmed as TT or BT leprosy, BI =O by histopathology.
Patients were randomly assigned to one of the fo llowing treatment regimens:
Treatment A (TrA) RMP 1500 mg single dose, supervised, fo llowed by I year DDS 100 mg daily, unsupervised. Treatment U (TrU) RMP 40 mg/K bodyweight, single dose. Patients were weighed and RMP administered as 300 and 150 mg capsules, fo llowing a list of bodyweights, to reach or approach the 40 mg/K dose.
In the case of remote villages, randomization was done by village rather than on an individual basis.
In the reference laboratory in Antwerp, and after treatment was started in the field, the patients were stratified according to BI (BI = 0 and BI = I) and clinical symptoms: less than 3 ( -31) and 3 or more skin lesions ( + 31). Patients were fo llowed clinically and by histopathology. A few patients had a skin biopsy at one year after the start of treatment, all had a biopsy at two years and thereafter at yearly intervals until no more signs of leprosy were fo und. A biopsy was also taken if aggravation was noted. The histopathology readings were done by an investigator who was not informed of the treatment regimen administered. The efficacy of the treatment regimens was evaluated by the proportion of patients cured and the relapse rate after cure, cure being defined as the absence of histopathological signs of leprosy, relapse as the reappearance of signs of leprosy in a biopsy after the initial histopathological cure.
For the analysis of results the life table technique was applied to take into account the withdrawal of some patients. For comparison of results the log-rank test was applied with significance at the 0·05 level. For comparison of relapse rates Fisher's exact test was applied.
Results
During 1983-85, 627 patients were taken into the study, 14 patients died from unrelated causes and 126 (2 1 %) patients were lost to fo llow-up (FU) within the first year after the start of treatment, leaving 487 for analysis, 247 on treatment A and 240 on treatment U. The results were analysed separately for patients with a BI = I and those with a HI = 0, and among the latter, patients with less than 3 or with 3 or more skin lesions.
The cumulative, yearly percentages of cure after the start of treatment for patients with a HI = ° are presented in Table I . There are no statistically significant differences between patients with less than 3 or with 3 or more skin lesions in either regimen or between the two regimens, although the patients with a small number of lesions tend to evolve somewhat more rapidly, particularly in regimen U at 36 months. Table 2 shows the results in patients with a BI = I. For this group of patients no stratification for the number of skin lesions was made because of the small numbers, the majority having more than 3 skin lesions: only one patient in regimen A and 2 patients in regimen U had less than 3 skin lesions. The cumulative cure rate for the patients treated with a single dose of RMP reaches only 76% at 48 months, however none of the patients not cured up to that time were seen at 60 months. The cumulative percentages of cure at any interval are not significantly different between the two regimens, nor between the patients with either IB = ° or BI = I. However, the absence of a significant difference, between the patients with a HI = I and treated with a single dose of RMP and all the other groups results from the small number of patients in the U group with a BI = 1.
Reappearance of a histological leprosy lesion in fo llow-up biopsies were observed in 26 cases. Two cases in the group BI = 0, treatment A with more than 3 skin lesions, were accompanied by definite clinical signs of reversal reaction: thickening of the upper lip region, or lagophthalmos with a thickened cervical nerve, appearing respectively at 37 • See Patients and methods. t Of whom one patient with less than 3 skin lesions. t Of whom two patients with less than 3 skin lesions.
and 39 months after the start of treatment. In 3 other cases the histological lesions resolved spontaneously in the next biopsy (all 3 in the BI = 0 group, with more than 3 skin lesions, 2 cases with treatment A and I case with treatment U). These 5 cases were interpreted as reversal reactions leaving a total of 21 relapses. Table 3 presents for each patient group the number of relapses, the incidence per 100 patients years of fo llow-up and the delay of appearance after the start of therapy. There is a gradual increase of relapse rates from group (a) (BI = 0, less than 3 skin lesions, treatment A) to (f) (BI = 1, more than 3 skin lesions, treatment U) with the exception of group (e). The only statistical significant differences are between patients in treatment group A with BI = 0 and less than 3 skin lesions and all the patients in treatment groups U. Relapses appear 3-5 years after the start of treatment, with a majority, 66·6%, at 4 years. The regimens, particularly the single dose RMP regimen, were well tolerated, no side effects were observed. There were no significant differences between regimens A and U with respect to increase of mutilations and hypertrophied nerves between the start of treatment and the last fo llow-up examination (data not shown).
Discussion
Based on calculations made by Shepard8 a BI = I corresponds to a total bacterial load of 107 My cobacterium leprae and a BI = b to 106 or less. Since a single dose of RMP kills at least 5 . 103 M. leprae,8 it may be expected that the infecting M. leprae in some PB patients will be eradicated by a single dose of the drug, while in others they will be reduced to very low numbers, of the order of 102-104, which may be expected to be eliminated by the immune mechanisms of the patients, as is the rule in other infectious diseases treated with antibiotics. We therefore compared a single dose RMP treatment with regimen A, known from a previous study to give excellent results and particularly suited for many situations in developing countries. I Single dose treatment of infectious diseases are presently known for giardiasis, gonorrhoea, 9 vaginal trichomoniasislO and candidiasis, II bacterial vaginosis,12 primary syphilis,1 3 lower urinary tract infection,1 4 meningococcal meningitis,1 5 and typhus.1 6 These treatments are based on the use of either long acting drugs (benzathine penicillin for syphilis, ceftriaxone for gonorrhoea, long acting chloramphenicol for meningococcal meningitis, doxycycline for typhus) or the administration of a drug in a high dose (ampicillin for gonorrhoea, metronidazole for trichomoniasis or bacterial vaginosis, drugs active against urinary pathogens). The advantages of this type of treatment are low cost, fe wer side-effects and maximal supervision. Since most leprosy cases in the world belong to the PB group, the advantages of a single dose treatment are obvious.
In the present study, among the patients with a BI = 0, the cure rate after a single high dose of RMP is identical with that after regimen A, although there is a slight tendency for some slower progress at 36 months after the start of treatment. However, for PB patients with a BI = 1 the cure rate of 76% obtained after treatment U is unacceptable. The shortcoming of treatment U is fu rther illustrated by the rising incidence of the relapse rate from 1·3 to 1·7% among patients with a BI = 0 to 3·6% among patients with a BI = 1. The only statistically significant differences between the different regimens are between U and A (Table 3 bottom) .
The single high dose RMP treatment presented here has too many shortcomings to be used on a wide scale.
The weight adjusted dosage is too cumbersome, single dose therapy could only be practical if a less stringent dosage could be administered. The necessity for a high dose, which was derived fr om experiments in mice,8 could be questioned, although the pharmacokinetics of RMP is more fa vourable in mouse than in man.17
But the most important observation is that patients with a BJ = I should be excluded from treatment U. In the present study, the distinction between BI = 0 and BI = I was always made by histopathology, when a bacillus was observed in a nerve twig. This procedure is inapplicable in control programmes.
In this study we were once more confronted with the unsolved problem of the distinction between relapse and reversal reaction in PB leprosy, although taking into consideration the clinical data, 5/26 histopathological relapses were compatible with reversal reactions, but it seems that the maximum incidence of relapses is situated at 3-4 years after the start of treatment. Un ensayo terapeutico limitado sobre la lepra paucibacilar comparando los efectos de una dosis {mica de rifampicina con los de una dosis imica de rifampicin a seguida de una dosis diaria de dapsona durante un aDO
Resumen Se compararon los indices de recuperaci6n completa de dos regimenes de tratamiento para la lepra paucibacilar (PB) por medio de una prueba anticipada aleatorizada: el primer tratamiento (U), una dosis unica de rifampicina de 40 mg por kilo de peso ye1 segundo (A), una dosis unica de 1500 mg de rifampicina, seguida de una dosis diaria de 100 mg de dapsona durante un ano. En el caso de los pacientes con un BI = 0, los indices de recuperaci6n ca1culados a partir de la histopatologia de biopsias cutimeas resultaron ser identicos para los dos regimenes. En cambio, aquellos pacientes con BI = I, mostraron indices de recuperaci6n y de recaida inadmisibles. Por esta raz6n, y dada la necesidad de separar a los pacientes segun el BI obtenido en las biopsias cutimeas, el regimen de dosis unica no parece ser adecuado para la utilizaci6n a gran escala.
